Thus, other OC biomarkers that are currently in development may be considered in a panel, such as RNA (38, 39), DNA methylation (40–42), circulating tumor cells (CTCs), and circulating tumor DNA (ctDNA) (43–45), the Cu isotope, and markers within exosomes, GSTT1, FOLR1, ALDH1, and mRNAs, most likely in conjunction with CA125 (32). The gene discussed is MUC16; the disease is neoplasm.